NC
IGMS

nVerses Capital’s IGM Biosciences IGMS Stock Holding History

nVerses Capital’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,600
Closed -$15.4K – 1101
2024
Q1 		$15.4K Buy
+1,600
New +$18.5K 0.04% 436

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

nVerses Capital's IGMS Position: Q2 2024 in Review

nVerses Capital sold out of IGM Biosciences (IGMS) in Q2 2024, closing a stake of 1,600 shares — an estimated $15.4K sold.

nVerses Capital first reported a position in IGMS in Q1 2024 and held it in 1 quarter. The position peaked at $15.4K in Q1 2024. 82 funds tracked by Wall St. Rank hold IGMS as of Q2 2024.

  • nVerses Capital reported no remaining IGM Biosciences position as of Q2 2024 after selling out during the quarter.
  • nVerses Capital sold 1,600 IGM Biosciences shares in Q2 2024, an estimated $15.4K.
  • nVerses Capital first reported a position in IGM Biosciences in Q1 2024 and held it in 1 quarter.
  • nVerses Capital's IGM Biosciences position peaked at $15.4K in Q1 2024.
  • 82 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2024.

Based on nVerses Capital's 13F filing for Q2 2024, filed 31 Jul 2024.